Ron Bose
- Oncology top 0.5%
- HER2/EGFR in Cancer Research 46
- Cancer Treatment and Pharmacology 11
- Colorectal Cancer Treatments and Studies 9
- Cancer Research top 1%
- Cancer Genomics and Diagnostics 19
- Molecular Biology top 2%
-
- Monoclonal and Polyclonal Antibodies Research 20
-
- Advanced Breast Cancer Therapies 25
- Gastric Cancer Management and Outcomes 16
- Lung Cancer Treatments and Mutations 12
- Co-authors
- Richard KolesnickMarcel VerheijAdriana Haimovitz‐FriedmanJohn KyriakisLeonard I. ZonÉva SzabóW. David JarvisXin Lin
- Journals
- Cancer Research (20 papers)Journal of Clinical Oncology (20 papers)Clinical Cancer Research (4 papers)
- Partner nations
- United StatesUnited KingdomSpain
In The Last Decade
Ron Bose
89 papers receiving 6.6k citations
Hit Papers
Peers
Comparison fields: 5 of 128
- Oncology 3.1k
- Cancer Research 1.2k
- Molecular Biology 3.5k
- Radiology, Nuclear Medicine and Imaging 1.0k
- Pulmonary and Respiratory Medicine 1.3k
Countries citing papers authored by Ron Bose
This map shows the geographic impact of Ron Bose's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ron Bose with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ron Bose more than expected).
Fields of papers citing papers by Ron Bose
This network shows the impact of papers produced by Ron Bose. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ron Bose. The network helps show where Ron Bose may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Ron Bose, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 0 | |
| 3 | 2023 | 4 | |
| 4 | 2022 | 1 | |
| 5 | 2020 | 3 | |
| 6 | Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket studybreakdown → | 2019 | 383 |
| 7 | Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Studybreakdown → | 2018 | 357 |
| 8 | 2017 | 11 | |
| 9 | 2017 | 10 | |
| 10 | 2016 | 115 | |
| 11 | 2016 | 38 | |
| 12 | 2015 | 218 | |
| 13 | 2014 | 12 | |
| 14 | Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancerbreakdown → | 2012 | 600 |
| 15 | 2011 | 80 | |
| 16 | 2009 | 53 | |
| 17 | 2006 | 51 | |
| 18 | 2000 | 10 | |
| 19 | 2000 | 21 | |
| 20 | 1998 | 37 |
About Ron Bose
Ron Bose is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Molecular Biology, having authored 94 papers that have together received 6.7k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (46 papers), Advanced Breast Cancer Therapies (25 papers), Monoclonal and Polyclonal Antibodies Research (20 papers), Cancer Genomics and Diagnostics (19 papers), Gastric Cancer Management and Outcomes (16 papers), Lung Cancer Treatments and Mutations (12 papers), Cancer Treatment and Pharmacology (11 papers) and Colorectal Cancer Treatments and Studies (9 papers). The work is most often cited by research in Oncology (3.1k citations), Cancer Research (1.2k citations), Molecular Biology (3.5k citations), Radiology, Nuclear Medicine and Imaging (1.0k citations) and Pulmonary and Respiratory Medicine (1.3k citations). Ron Bose has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Richard Kolesnick, Marcel Verheij, Adriana Haimovitz‐Friedman, John Kyriakis, Leonard I. Zon, Éva Szabó, W. David Jarvis, Xin Lin, Zvi Fuks and Zvi Fuks. Their work appears in journals such as Cancer Research, Journal of Clinical Oncology, Clinical Cancer Research, Journal of Biological Chemistry and Molecular & Cellular Proteomics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.